Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in Apellis Pharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 256
- −59 vs. Q2 2023
- Shares held
- 113.9M
- +8.45M (+8.0%) vs. Q2 2023
- Total value
- $4.34B
- −$5.27B (−54.8%) vs. Q2 2023
- New holders
- 47
- 126 more added
- Sold out
- 106
- 65 more reduced
2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APLS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $10.2K |
| Q1 2026 | 324 | $5.56B |
| Q4 2025 | 280 | $3.17B |
| Q3 2025 | 273 | $2.77B |
| Q2 2025 | 247 | $2.28B |
| Q1 2025 | 255 | $2.80B |
| Q4 2024 | 260 | $4.04B |
| Q3 2024 | 265 | $3.41B |
| Q2 2024 | 263 | $4.43B |
| Q1 2024 | 302 | $6.65B |
| Q4 2023 | 284 | $6.82B |
| Q3 2023 | 256 | $4.34B |
| Q2 2023 | 317 | $9.71B |
| Q1 2023 | 282 | $7.28B |
| Q4 2022 | 244 | $5.20B |
| Q3 2022 | 250 | $6.66B |
| Q2 2022 | 212 | $4.15B |
| Q1 2022 | 212 | $4.62B |
| Q4 2021 | 187 | $3.83B |
| Q3 2021 | 181 | $2.29B |
| Q2 2021 | 205 | $4.08B |
| Q1 2021 | 175 | $2.80B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Apellis Pharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| 683 Capital Management, LLC | 240,000 | $9.13M | 0.93% | +195,700+441.8% | Added |
| Acuta Capital Partners, LLC | 244,484 | $9.30M | 6.76% | −53,112−17.8% | Reduced |
| Fiduciary Trust Co | 265,207 | $10.1M | 0.18% | −8,709−3.2% | Reduced |
| Jane Street Group, LLC | 273,226 | $10.4M | 0.02% | −207,856−43.2% | Reduced |
| Caption Management, LLC | 273,250 | $10.4M | 1.34% | +273,026+121,886.6% | Added |
| Nuveen Asset Management, LLC | 273,513 | $10.4M | 0.00% | +11,115+4.2% | Added |
| Bank of Nova Scotia | 293,305 | $11.2M | 0.03% | +288,685+6,248.6% | Added |
| Prudential Financial Inc | 303,560 | $12.0M | 0.02% | +126,480+71.4% | Added |
| Deutsche Bank AG | 324,294 | $12.3M | 0.01% | −154,072−32.2% | Reduced |
| Candriam Luxembourg S.C.A. | 326,507 | $12.4M | 0.10% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 331,793 | $12.6M | 0.00% | −303,104−47.7% | Reduced |
| Barclays PLC | 342,889 | $13.0M | 0.01% | +30,659+9.8% | Added |
| Ameriprise Financial Inc | 352,392 | $13.4M | 0.00% | +211,314+149.8% | Added |
| Amundi | 278,964 | $13.5M | 0.01% | +242,860+672.7% | Added |
| Bank of New York Mellon Corp | 360,287 | $13.7M | 0.00% | +2,998+0.8% | Added |
| TD Asset Management Inc | 370,857 | $14.1M | 0.02% | −107,869−22.5% | Reduced |
| Susquehanna International Group, LLP | 372,785 | $14.2M | 0.02% | +56,875+18.0% | Added |
| First Trust Advisors LP | 398,138 | $15.1M | 0.02% | +320,847+415.1% | Added |
| New York State Common Retirement Fund | 402,944 | $15.3M | 0.02% | +101,949+33.9% | Added |
| Eagle Asset Management Inc | 449,970 | $17.1M | 0.10% | −962−0.2% | Reduced |
| Northern Trust Corp | 450,430 | $17.1M | 0.00% | −401,842−47.1% | Reduced |
| Bank of Montreal | 431,973 | $19.3M | 0.01% | +354,047+454.3% | Added |
| Invesco Ltd. | 540,676 | $20.6M | 0.01% | −611,720−53.1% | Reduced |
| Westfield Capital Management Co LP | 548,870 | $20.9M | 0.14% | −47,362−7.9% | Reduced |
| Frazier Life Sciences Management, L.P. | 614,043 | $23.4M | 1.55% | +614,043 | New |
| Bank of America Corp | 704,955 | $26.8M | 0.00% | +295,113+72.0% | Added |
| Pictet Asset Management Holding SA | 734,150 | $27.9M | 0.03% | +734,150 | New |
| Victory Capital Management Inc | 738,511 | $28.1M | 0.03% | +337,554+84.2% | Added |
| Logos Global Management LP | 750,000 | $28.5M | 4.07% | +125,000+20.0% | Added |
| Bellevue Group AG | 793,841 | $30.2M | 0.49% | +275,346+53.1% | Added |
| Charles Schwab Investment Management Inc | 879,357 | $33.5M | 0.01% | +50,835+6.1% | Added |
| Iron Triangle Partners LP | 880,000 | $33.5M | 4.89% | +880,000 | New |
| Fiera Capital Corp | 919,690 | $35.0M | 0.11% | +391,770+74.2% | Added |
| Assenagon Asset Management S.A. | 1,023,507 | $38.9M | 0.14% | +524,797+105.2% | Added |
| Norges Bank | 1,052,193 | $40.0M | 0.01% | +29,167+2.9% | Added |
| Polar Capital Holdings Plc | 1,053,875 | $40.1M | 0.30% | +588,875+126.6% | Added |
| Macquarie Group Ltd | 1,076,548 | $41.0M | 0.05% | +301,068+38.8% | Added |
| OrbiMed Advisors LLC | 1,260,500 | $47.9M | 1.11% | +350,300+38.5% | Added |
| Geode Capital Management, LLC | 1,554,826 | $59.2M | 0.01% | +56,437+3.8% | Added |
| Morgan Stanley | 1,608,996 | $61.2M | 0.01% | +852,331+112.6% | Added |
| Artal Group S.A. | 1,664,572 | $63.3M | 2.76% | +614,505+58.5% | Added |
| Boxer Capital, LLC | 1,726,000 | $65.7M | 3.50% | +150,000+9.5% | Added |
| Price T Rowe Associates Inc | 1,783,241 | $67.8M | 0.01% | −5,288,985−74.8% | Reduced |
| Cormorant Asset Management, LP | 2,000,000 | $76.1M | 4.44% | +690,000+52.7% | Added |
| Slate Path Capital LP | 2,068,000 | $78.7M | 2.19% | +2,068,000 | New |
| JPMorgan Chase & Co | 2,217,747 | $84.4M | 0.01% | +430,765+24.1% | Added |
| FMR LLC | 2,259,766 | $86.0M | 0.01% | −1,965,829−46.5% | Reduced |
| Octagon Capital Advisors LP | 3,130,000 | $119.1M | 20.96% | +511,700+19.5% | Added |
| State Street Corp | 3,238,114 | $123.2M | 0.01% | +955,029+41.8% | Added |
| Jennison Associates LLC | 3,542,209 | $134.7M | 0.11% | +1,571,606+79.8% | Added |
| BlackRock Inc. | 5,272,746 | $200.6M | 0.01% | −474,881−8.3% | Reduced |
| T. Rowe Price Investment Management, Inc. | 6,519,471 | $248.0M | 0.18% | +880,596+15.6% | Added |
| Vanguard Group Inc | 9,469,977 | $360.2M | 0.01% | +68,687+0.7% | Added |
| EcoR1 Capital, LLC | 10,899,859 | $414.6M | 14.13% | +5,448,212+99.9% | Added |
| Avoro Capital Advisors LLC | 11,111,111 | $422.7M | 6.59% | 00.0% | Unchanged |
| Wellington Management Group LLP | 15,167,044 | $577.0M | 0.12% | +8,502,769+127.6% | Added |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −1,239,361−100.0% | Sold out |
| Lord, Abbett & Co. LLC | 0 | $0 | 0.00% | −1,068,143−100.0% | Sold out |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −812,037−100.0% | Sold out |
| 1832 Asset Management L.P. | 0 | $0 | 0.00% | −661,700−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −522,929−100.0% | Sold out |
| Avidity Partners Management LP | 0 | $0 | 0.00% | −468,700−100.0% | Sold out |
| Nicholas Investment Partners, LP | 0 | $0 | 0.00% | −414,419−100.0% | Sold out |
| Eventide Asset Management, LLC | 0 | $0 | 0.00% | −397,141−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −313,289−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −309,024−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −304,169−100.0% | Sold out |
| PFM Health Sciences, LP | 0 | $0 | 0.00% | −274,498−100.0% | Sold out |
| Finepoint Capital LP | 0 | $0 | 0.00% | −241,690−100.0% | Sold out |
| Ghost Tree Capital, LLC | 0 | $0 | 0.00% | −180,000−100.0% | Sold out |
| AXA S.A. | 0 | $0 | 0.00% | −173,495−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −165,710−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −149,976−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −147,465−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −138,513−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −133,800−100.0% | Sold out |
| Senator Investment Group LP | 0 | $0 | 0.00% | −130,000−100.0% | Sold out |
| International Biotechnology Trust PLC | 0 | $0 | 0.00% | −129,700−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −114,713−100.0% | Sold out |
| Saturn V Capital Management LLC | 0 | $0 | 0.00% | −107,406−100.0% | Sold out |
| Polar Asset Management Partners Inc. | 0 | $0 | 0.00% | −105,810−100.0% | Sold out |
| Artia Global Partners LP | 0 | $0 | 0.00% | −102,940−100.0% | Sold out |
| Kornitzer Capital Management Inc | 0 | $0 | 0.00% | −100,545−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −94,783−100.0% | Sold out |
| Clough Capital Partners L P | 0 | $0 | 0.00% | −83,679−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −72,000−100.0% | Sold out |
| Putnam Investments LLC | 0 | $0 | 0.00% | −65,918−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −65,475−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −62,737−100.0% | Sold out |
| Brookfield Asset Management Inc. | 0 | $0 | 0.00% | −61,414−100.0% | Sold out |
| WCM Investment Management, LLC | 0 | $0 | 0.00% | −59,064−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −51,988−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Castleark Management LLC | 0 | $0 | 0.00% | −40,820−100.0% | Sold out |
| Calamos Advisors LLC | 0 | $0 | 0.00% | −35,133−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −33,187−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −31,203−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −31,186−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −30,242−100.0% | Sold out |
| Weiss Multi-Strategy Advisers LLC | 0 | $0 | 0.00% | −27,169−100.0% | Sold out |